Back

Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?

European Heart Journal

18 January 2019
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Myocardial Disease Pharmacology and Pharmacotherapy

Abstract

Abstract

Contributors

Rodney H Falk
Rodney H Falk

Author

You may be interested in
thumbnail
Congress Presentation
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy
29 June 2021
thumbnail
Congress Presentation
Transthyretin inherited cardiac amyloidosis: Mutidisciplinary approach
9 December 2022
thumbnail
Webinar
New drugs in the treatment of amyloidosis
16 July 2025
thumbnail
ESC Journals
Characteristics and natural history of early-stage cardiac transthyretin amyloidosis
24 May 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources